PMID- 18518884
OWN - NLM
STAT- MEDLINE
DCOM- 20090116
LR  - 20101118
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 35
IP  - 9
DP  - 2008 Sep
TI  - Association between mu-opioid receptor-1 102T>C polymorphism and intermediate 
      type 2 diabetes phenotypes: results from the Quebec Family Study (QFS).
PG  - 1018-22
LID - 10.1111/j.1440-1681.2008.04972.x [doi]
AB  - It has been suggested recently that molecules expressed both in the pancreas and 
      hypothalamus, such as mu-opioid receptor 1 (OPRM1), could form an integrated 
      brain-liver system, which may sense glucose levels and therefore contribute to 
      the development of type 2 diabetes mellitus (T2DM). In the present study, we 
      tested associations between OPRM1 gene polymorphisms (rs1799971, 102T/C and 
      rs0648007G/A) and indices of glucose tolerance, insulin sensitivity (IS) and 
      insulin secretion derived from plasma measures obtained in a fasting state and 
      following a 75 g oral glucose tolerance test (OGTT) in 749 subjects from the 
      Quebec Family Study (QFS). Polymorphisms were tested for association with glucose 
      tolerance (normal vs IFG and T2DM combined) by calculating a chi(2) statistic and 
      corresponding P values, whereas associations with quantitative measures of 
      glucose tolerance, IS and insulin secretion were tested using mixed linear models 
      implemented in the MIXED procedure of sas (SAS Institute, Cary, NC, USA). 
      Associations were found between 102T/C OPRM1 and indices of glucose tolerance and 
      IS. Compared with T/T homozygotes, carriers of the OPRM1 C-102 variant exhibited 
      a better glucose tolerance with a lower (P = 0.006) glucose area under the curve 
      (AUC) following the OGTT and a better IS with a higher (P = 0.03) value of the 
      Cederholm index, a numerical index of the curve relating glucose uptake to the 
      log(10) plasma insulin levels during the OGTT. The results of the present study 
      reveal that the 102T/C OPRM1 gene polymorphism is associated with a better 
      glucose tolerance and improved IS, both of which suggest a potential protective 
      effect of this variant on T2DM risk.
FAU - Ruchat, Stephanie-May
AU  - Ruchat SM
AD  - Department of Preventive Medicine, Division of Kinesiology, Laval University, 
      Quebec, Canada.
FAU - Girard, Martine
AU  - Girard M
FAU - Weisnagel, S John
AU  - Weisnagel SJ
FAU - Bouchard, Claude
AU  - Bouchard C
FAU - Vohl, Marie-Claude
AU  - Vohl MC
FAU - Perusse, Louis
AU  - Perusse L
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080601
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (OPRM1 protein, human)
RN  - 0 (Receptors, Opioid, mu)
SB  - IM
MH  - Adult
MH  - Diabetes Mellitus, Type 2/*genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Linkage
MH  - Genetic Predisposition to Disease
MH  - Glucose Intolerance/genetics
MH  - Glucose Tolerance Test
MH  - Humans
MH  - Insulin Resistance/genetics
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - *Polymorphism, Single Nucleotide
MH  - Quebec
MH  - Receptors, Opioid, mu/*genetics
MH  - Risk Factors
EDAT- 2008/06/04 09:00
MHDA- 2009/01/17 09:00
CRDT- 2008/06/04 09:00
PHST- 2008/06/04 09:00 [pubmed]
PHST- 2009/01/17 09:00 [medline]
PHST- 2008/06/04 09:00 [entrez]
AID - CEP4972 [pii]
AID - 10.1111/j.1440-1681.2008.04972.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2008 Sep;35(9):1018-22. doi: 
      10.1111/j.1440-1681.2008.04972.x. Epub 2008 Jun 1.